Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
PHASE2CompletedINTERVENTIONAL
Enrollment
388
Participants
Timeline
Start Date
July 1, 2016
Primary Completion Date
February 28, 2022
Study Completion Date
February 28, 2022
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BIOLOGICAL
Pembrolizumab
Intravenous infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02787005 - Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | Biotech Hunter | Biotech Hunter